Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Quoin Pharmaceuticals, Ltd. Sponsored ADR (QNRX : NSDQ)

• Company Description    Quoin Pharmaceuticals is a specialty pharmaceutical company focused on rare and orphan diseases. Quoin Pharmaceuticals, formerly known as Cellect Biotechnology Ltd., is based in Tel Aviv. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $7.60 Daily Weekly Monthly 20 Day Moving Average: 2,293 shares Shares Outstanding: 0.59 (millions) Market Capitalization: $4.47 (millions) Beta: 1.59 52 Week High: $45.50 52 Week Low: $5.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.04% 2.21% 12 Week -9.50% -17.79% Year To Date -66.60% -70.37%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 42127 Pleasant Forest Court - Ashburn,VA 20148 USA ph: 703-980-4182 fax: 972-9767-8750 ir@cellectbio.com https://quoinpharma.com

• General Corporate Information    Officers Michael Myers - Chairman and Chief Executive Officer Denise Carter - Chief Operating Officer Gordon Dunn - Chief Financial Officer Joseph Cooper - Director James Culverwell - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 74907L409 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 0.59 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.59 Market Capitalization: $4.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-6.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-25.57 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.75 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 53.95% vs. Previous Quarter: 3.38% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -210.50 03/31/25 - -148.97 12/31/24 - -114.71 ROA 06/30/25 - -99.41 03/31/25 - -77.23 12/31/24 - -62.59 Current Ratio 06/30/25 - 1.96 03/31/25 - 2.57 12/31/24 - 3.57 Quick Ratio 06/30/25 - 1.96 03/31/25 - 2.57 12/31/24 - 3.57 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 4.34 03/31/25 - 10.07 12/31/24 - 35.47 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©